Risperidone ER is under clinical development by Lyndra Therapeutics and currently in Phase I for Bipolar I Disorder. According to GlobalData, Phase I drugs for Bipolar I Disorder does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Risperidone ER LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Risperidone ER overview

Risperidone ER is under development for the treatment of schizophrenia, schizoaffective disorder and bipolar 1 disorder. It is administered through oral route. The drug candidate is formulated as extended-release capsule. It acts by targeting D2 receptor and 5-HT2 receptor. The drug candidate is developed based on ultra long-acting oral drug delivery technology. In this technology, the dosage form is encapsulated in a gelatin capsule and it has star-shaped configuration.

Lyndra Therapeutics overview

Lyndra Therapeutics (Lyndra) is a biopharmaceutical company that develops long-acting oral therapies. The company’s therapeutic area pipeline products include risperidone LYN-005, aripiprazole LYN-006, dapaglifozin LYN-045 and rosuvastatin LYN-047. Lyndra also offers levomethadone LYN-014, buprenorphine LYN-013, monthly oral contraception LYN-064 and biweekly ivermectin LYN-163. Its product treatment includes various diseases such as schizophrenia and bipolar 1 disorder, psychiatric conditions, diabetes, dyslipidemia, opioid use disorder, pregnancy prevention and malaria eradication. The company also delivers medicines in an oral form through its drug delivery platform. Lyndra is headquartered in Watertown, Massachusetts, the US.

For a complete picture of Risperidone ER’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.